The first made-in-Canada COVID-19 vaccine will begin human clinical trials on Tuesday, according to a Toronto-based biotechnology company. Providence Therapeutics said 60 volunteers between the ages of 18 to 65 will be divided into three groups, and three different dose levels of the vaccine and a placebo will be administered to each group. These volunteers will be monitored for a total of 13 months, but enough data will have been collected by April 2021 to move on to Phase 2 in May 2021. “Having a made-in-Canada solution to address the global COVID-19 pandemic will augment the reliability of vaccine supply for Canadians, contribute to the global vaccine supply, and position a Canadian company on the global stage as a contributor to the solution,” said Brad Sorenson, founder and CEO of Providence Therapeutics. The vaccine, known as PTX-COVID19-B, is an mRNA vaccine similar to the Moderna COVID-19 vaccine which now being distributed in Canada. …